We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

118 hedge funds and large institutions have $163M invested in Rigel Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 39 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,988% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $25K

8% more capital invested

Capital invested by funds: $150M → $163M (+$12.7M)

5% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 39

1.11% less ownership

Funds ownership: 7.4% → 6.29% (-1.1%)

14% less funds holding

Funds holding: 138 → 118 (-20)

61% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 33

Holders
118
Holders Change
-20
Holders Change %
-14.49%
% of All Funds
1.9%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
37
Reduced
39
Closed
33
Calls
$1.02M
Puts
$25K
Net Calls
+$997K
Net Calls Change
+$583K

Top Buyers

1
AC
Armistice Capital
New York
+$12.4M
2
DZ Bank
DZ Bank
Germany
+$1.34M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.25M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.24M
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$525K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.05M
2
Invesco
Invesco
Georgia
-$4.58M
3
Millennium Management
Millennium Management
New York
-$3.68M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$3.03M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$25.4M +$12.4M +1,350,313 +391%
BlackRock
2
BlackRock
New York
$22M -$1.37M -149,918 -9%
Vanguard Group
3
Vanguard Group
Pennsylvania
$18.1M +$130K +14,160 +1%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$13.3M -$6.05M -659,458 -43%
Jacobs Levy Equity Management
5
Jacobs Levy Equity Management
New Jersey
$6.48M +$1.25M +136,247 +46%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$5.31M +$1.24M +134,964 +62%
State Street
7
State Street
Massachusetts
$5.06M -$461K -50,316 -13%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$5.03M -$1.19M -129,356 -28%
Millennium Management
9
Millennium Management
New York
$4.78M -$3.68M -401,466 -56%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$4.72M +$57.8K +6,306 +2%
VOYA Investment Management
11
VOYA Investment Management
Georgia
$4.5M -$549K -59,910 -17%
N
12
Nuveen
North Carolina
$4.08M +$421K +45,879 +20%
TA
13
Tamarack Advisers
California
$3.45M +$275K +30,000 +15%
SFM
14
Sphera Funds Management
Israel
$3.42M +$107K +11,626 +5%
DZ Bank
15
DZ Bank
Germany
$3.31M +$1.34M +146,616 +199%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$2.7M -$137K -14,930 -8%
Citadel Advisors
17
Citadel Advisors
Florida
$2.65M -$2.58M -281,535 -61%
Macquarie Group
18
Macquarie Group
Australia
$2.4M – – –
Two Sigma Investments
19
Two Sigma Investments
New York
$2.34M +$27.4K +2,986 +2%
Northern Trust
20
Northern Trust
Illinois
$2.26M -$97.6K -10,647 -7%
CM
21
CM Management
Florida
$2.25M +$183K +20,000 +15%
RPAM
22
Rhenman & Partners Asset Management
Sweden
$1.84M – – –
Assenagon Asset Management
23
Assenagon Asset Management
Luxembourg
$1.24M -$1.7M -185,499 -69%
PAM
24
Panagora Asset Management
Massachusetts
$1.24M +$173K +18,914 +30%
Charles Schwab
25
Charles Schwab
California
$1.2M -$63.2K -6,889 -8%
1
2 3 4 5

RIGL Hedge Fund Activity: Q4 2022 in Review

118 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2022, worth a combined $163M — up 8.5% from $150M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of RIGL and 13 opened new positions — a net loss of 20 holders — while 39 trimmed existing stakes and 37 added.

The largest buyer was Armistice Capital, adding an estimated $12.4M. The largest seller was Fidelity Investments, cutting an estimated $6.05M.

  • 118 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2022, down from 138 in Q3 2022.
  • Funds reported $163M of Rigel Pharmaceuticals stock for Q4 2022, up 8.5% quarter-over-quarter.
  • 13 funds opened new Rigel Pharmaceuticals positions in Q4 2022 and 33 closed out, a net change of -20 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2022 was Armistice Capital, an estimated $12.4M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2022 was Fidelity Investments, an estimated $6.05M sold.

Based on aggregated 13F filings for Q4 2022.